1. Home
  2. Labeler Index
  3. Bluepoint
  4. 68001-414
  5. Product Images: Duloxetine

Product Images Duloxetine

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 13 images provide visual information about the product associated with Duloxetine NDC 68001-414 by Bluepoint, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1: Kaplan-Meier Estimation of Cumulative Proportion of Patients with Relapse (MDD Study 5) - duloxetine fig1

Figure 1: Kaplan-Meier Estimation of Cumulative Proportion of Patients with Relapse (MDD Study 5) - duloxetine fig1

Duloxetine DR Capsules USP rev 09 2019 - duloxetine fig10

Duloxetine DR Capsules USP rev 09 2019 - duloxetine fig10

duloxetine fig11

duloxetine fig11

Each capsule contains 337mg of duloxetine hydrochloride USP, equivalent to 30mg of duloxetine. It is a delayed-release capsule used in dosage as recommended by accompanying literature from Bluepoint Laboratories. The medication guide should be provided separately to each patient, and it should be kept out of the reach of children. The text also includes details about the product's manufacturer, Hyderabad-500 090, India, and NDC code 68001-414-04 RXONLY. It provides storage instructions, a product issue date, and a printed area's "Dotted lines not to be printed" warning but lacks details on use or a comprehensive description.*

duloxetine fig12

duloxetine fig12

This is a description for medication called Duloxetine Delayed-Release capsules manufactured by Aurobindo Pharma Limited. It contains 67.3mg of duloxetine hydrochloride USP. The usual dosage should be referenced from the accompanying materials provided by the manufacturer. The medication should be kept out of reach of children and stored at room temperature. The pharmacist should dispense the medication guide separately to each patient. The accompanying text contains some printing and coding information.*

fig2 - duloxetine fig2

fig2 - duloxetine fig2

Figure 3 - duloxetine fig3

Figure 3 - duloxetine fig3

Figure 4: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity - DPNP-2 - duloxetine fig4

Figure 4: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity - DPNP-2 - duloxetine fig4

Figure 7: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – CLBP-1 - duloxetine fig5

Figure 7: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – CLBP-1 - duloxetine fig5

The text is a chart showing the percentage of patients who experienced improvement in their pain levels after taking different dosages of duloxetine and a placebo. The chart also shows the percent improvement in pain from baseline for each group.*

Figure 8: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – CLBP-3 - duloxetine fig6

Figure 8: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – CLBP-3 - duloxetine fig6

This is a chart showing the percent improvement in pain from baseline for patients on different doses of duloxetine and placebo. The doses are 120mg, 60mg, and 20mg. The chart shows that as the dose of duloxetine increases, the percent improvement in pain also increases. The data is displayed on a scale of 0 to 100.*

Figure 9: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – OA-1 - duloxetine fig7

Figure 9: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – OA-1 - duloxetine fig7

The chart shows the percentage of patients who experienced improvement in pain after taking either a placebo or duloxetine (in doses of 60mg or 120mg once daily). The X-axis represents the percentage of patients improved while the Y-axis shows the baseline pain on the BOCF scale. The data is presented as a bar graph, with the placebo group having a percentage of zero, and duloxetine showing improvement in pain in percentages ranging from 20 to 100.*

Duloxetine DR Capsules BluePoint rev 09 2019 - duloxetine fig8

Duloxetine DR Capsules BluePoint rev 09 2019 - duloxetine fig8

The given text seems to be a chart or graph representing the percentage of patients improved with placebo and duloxetine based on the percent improvement in pain from baseline. It shows the improvement rate in terms of numbers and colors on a scale of 0 to 100. The graph also indicates the dosage frequency of duloxetine. No further information is given.*

Duloxetine DR Capsules 30 mg rev 09 2019 - duloxetine fig9

Duloxetine DR Capsules 30 mg rev 09 2019 - duloxetine fig9

The text is providing statistical data related to pain improvement in patients taking Placebo and Duloxetine. The recommended dosage of the medicine is 60/120 mg taken once a day. The graph showing the percentage of patients along with the percent improvement in pain from the baseline is also provided.*

Structure - duloxetine str

Structure - duloxetine str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.